Authors

Latest:

Telephone Counseling Boosts Spirits-and Immune Indicators-for Cervical Cancer Survivors

Psychosocial telephone counseling intervention benefits mood and quality of life for cervical cancer survivors, including cancer-specific and gynecologic concerns.

Christina Loguidice

Latest:

New Treatment Options Are in Play for Relapsed/ Refractory DLBCL

Up to 40% of patients with diffuse large B-cell lymphoma are refractory to or relapse after first-line treatment.

Christina M. Annunziata, MD, PhD

Latest:

Dr. Annunziata on Efforts to Prevent Gynecologic Cancers

Christina M. Annunziata, MD, PhD, investigator, Women's Malignancies Branch, head, Translational Genomics Section, National Cancer Institute, discusses the importance on efforts being done to prevent gynecologic cancers.

Christina T. Loguidice

Latest:

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Whom to Treat?

PARP inhibitors have emerged as agents that generate improved oncological outcomes in select patient populations with metastatic castration-resistant prostate cancer.

Christina Tan, MD, MPH

Latest:

Dr. Tan on the Risk of Novel Coronavirus for Patients With Cancer

Christina Tan, MD, MPH, discusses the potential impact of the novel coronavirus on patients with cancer.

Christine Bestvina, MD

Latest:

Looking Ahead in NSCLC Oncodrivers and Targeted Therapies

Panelists discuss how ASCO 2025 highlighted exciting advances in targeted therapy including neoadjuvant approaches, dynamic biomarkers like circulating tumor DNA, mixed results with HER3-directed antibody-drug conjugates (ADCs) in the EGFR space, but promising data with trastuzumab-based ADCs, emphasizing the critical importance of comprehensive biomarker testing to ensure no patients miss potentially life-changing targeted therapies.

Christine M. Duffy, MD, MPH

Latest:

Survivorship Starts at Diagnosis in Breast Cancer

The inclusion of patients from the time of diagnosis and encompassing family, friends, and caregivers is central to moving survivorship care forward, especially for breast cancer survivorship, which has high survival rates for early disease and the emergence of novel treatments for advanced cancers.

Christine N. Duncan, MD

Latest:

Narsoplimab Trial Results

The panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.

Christophe Mariette, MD, PhD

Latest:

Dr. Mariette on Takeaways from a Study of Esophageal and Gastric Cancer Surgery

Christophe Mariette, MD, PhD, surgical oncologist, professor of Surgery, University Hospital of Lille, discusses the main takeaways from a study investigating postoperative mortality after patients undergo surgery for esophageal and gastric cancer.

Christopher A. Klebanoff, MD

Latest:

Dr. Klebanoff on Biosimilars Reducing Financial Toxicity in Breast Cancer

Christopher A. Klebanoff, MD, discusses using biosimilars to reduce financial toxicity in breast cancer.

Christopher A. Yasenchak, MD

Latest:

Dr. Yasenchak on the Safety Profile of Brentuximab Vedotin/Nivolumab in Hodgkin Lymphoma

Christopher A. Yasenchak, MD, discusses the safety profile of brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.

Christopher B. Allard, MD

Latest:

Should You Pursue a Surgical Oncology Fellowship?

Christopher B. Allard, MD, shares his views on pursuing a surgical oncology fellowship.

Christopher Crane, MD

Latest:

Dr. Crane on the Use of Proton Therapy and the MR-Linear Accelerator in GI Malignancies

Christopher Crane, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the emergence and success of new technologies in the treatment of patients with gastrointestinal (GI) malignancies.

Christopher Dittus, DO, MPH

Latest:

How to Survive With Limited Finances (and a Family) as a Hematology-Oncology Fellow

If you are anything like me, despite working incredibly hard, not getting paid adequately for many years, and accumulating an incredible amount of debt, you could not imagine any other career.

Christopher E. Barbieri, MD, PhD

Latest:

Dr. Barbieri on SPOP Mutations in Prostate Cancer

Christopher E. Barbieri, MD, PhD, surgeon, researcher in prostate cancer genomics, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and New-York Presbyterian, discusses the implications of SPOP mutations in patients with prostate cancer.

Christopher E. Dandoy, MD, MSc

Latest:

Dr. Dandoy on Overcoming Challenges with TA-TMA

Christopher E. Dandoy, MD, MSc, shares advice for how to overcome the challenges in managing transplanted-associated thrombotic microangiopathy. The primary challenges are diagnosing and identifying TA-TMA in patients.

Christopher H. Crane, MD

Latest:

Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer

An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.

Christopher Heery, MD

Latest:

Dr. Heery on Advancements in Treatment of Neuroendocrine Tumors

Dr. Christopher Heery, medical oncologist, National Cancer Institute, discusses the progress that has been made in the treatment of patients with neuroendocrine tumors.

Christopher J. Hoimes, DO

Latest:

Dr. Hoimes on EV-103 Results in Urothelial Cancer

Christopher J. Hoimes, DO, discusses the results of the EV-103 trial in patients with locally advanced or metastatic urothelial cancer.

Christopher J. Kane, MD

Latest:

Dr. Kane on Challenges Facing Genetic Testing in Prostate Cancer

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses challenges facing genetic testing for patients with prostate cancer.